{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-288347","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2025-11-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.693788+00:00","generated_at":"2026-05-16T18:32:41.304969+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Invivyd prices $125M stock and warrant offering; net proceeds ~$117.2M for pipeline funding","bullets":["Priced 44M shares at $2.50 and 6M pre-funded warrants at $2.4999; gross $125M, net ~$117.2M.","Offering closed Nov 19, 2025; underwriters have 30-day option for 7.5M additional shares.","Proceeds for VYD2311 commercial prep, RSV/measles R&D, SPEAR Long COVID study, and working capital.","Cantor Fitzgerald sole book-runner; H.C. Wainwright lead manager."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-288347","json":"https://secwatch.observer/filing/0001193125-25-288347.json","markdown":"https://secwatch.observer/filing/0001193125-25-288347.md","text":"https://secwatch.observer/filing/0001193125-25-288347.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000119312525288347/0001193125-25-288347-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000119312525288347/ivvd-20251117.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T18:32:41.304969+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}